Barclays reaffirmed their overweight rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on Tuesday morning.
AZN has been the topic of a number of other reports. Goldman Sachs Group set a GBX 4,080 ($53.31) target price on shares of AstraZeneca and gave the stock a sell rating in a research report on Friday, November 16th. JPMorgan Chase & Co. set a GBX 7,100 ($92.77) price objective on shares of AstraZeneca and gave the company a buy rating in a report on Tuesday, January 29th. Shore Capital reissued a hold rating on shares of AstraZeneca in a report on Tuesday, November 6th. Bryan, Garnier & Co lowered shares of AstraZeneca to a neutral rating in a report on Thursday, November 8th. Finally, Deutsche Bank reissued a buy rating and set a GBX 6,900 ($90.16) price objective on shares of AstraZeneca in a report on Monday, January 14th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of GBX 6,243.45 ($81.58).
Get AstraZeneca alerts: Shares of LON:AZN opened at GBX 5,696 ($74.43) on Tuesday. AstraZeneca has a one year low of GBX 4,260 ($55.66) and a one year high of GBX 5,520 ($72.13).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: What is the S&P 500 Index?